preheader BJH 1

header website

Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Video-interview with Professor Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School
    of Medicine, Athens, Greece

2. Classic Hodgkin lymphoma (cHL) patients with high-risk features have greater benefit from brentuximab vedotin
    + AVD versus ABVD compared with the overall study population

3. Anti-tumor activity of compound CAR T cells targeting both CLL1 and CD33 in a variety of CLL1+ and CD33+
    leukemia cells in vitro and in vivo

4. Better response rates and increased MRD negativity with KRd compared to KCd in newly diagnosed multiple
    myeloma patients, including high-risk patients

5. The combination of ruxolitinib and azacitidine is well tolerated with good responses in patients with myelofibrosis


Banner Ninlaro 630 77 06 2018


Tanja van Harn, PhD


Medical writer

Back to Top